These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11071184)

  • 1. AIDS across Europe, 1994-98: the EuroSIDA study.
    Mocroft A; Katlama C; Johnson AM; Pradier C; Antunes F; Mulcahy F; Chiesi A; Phillips AN; Kirk O; Lundgren JD
    Lancet; 2000 Jul; 356(9226):291-6. PubMed ID: 11071184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.
    Dore GJ; Correll PK; Li Y; Kaldor JM; Cooper DA; Brew BJ
    AIDS; 1999 Jul; 13(10):1249-53. PubMed ID: 10416530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
    Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
    Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.
    De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Ndèye GF; Sow PS; Ndèye KC; Ecochard R; Delaporte E;
    BMC Infect Dis; 2010 Jun; 10():179. PubMed ID: 20565900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.
    Mocroft A; Furrer HJ; Miro JM; Reiss P; Mussini C; Kirk O; Abgrall S; Ayayi S; Bartmeyer B; Braun D; Castagna A; d'Arminio Monforte A; Gazzard B; Gutierrez F; Hurtado I; Jansen K; Meyer L; Muñoz P; Obel N; Soler-Palacin P; Papadopoulos A; Raffi F; Ramos JT; Rockstroh JK; Salmon D; Torti C; Warszawski J; de Wit S; Zangerle R; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Lundgren JD;
    Clin Infect Dis; 2013 Oct; 57(7):1038-47. PubMed ID: 23921881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women.
    Charurat M; Blattner W; Hershow R; Buck A; Zorrilla CD; Watts DH; Paul M; Landesman S; Adeniyi-Jones S; Tuomala R;
    J Womens Health (Larchmt); 2004; 13(6):719-30. PubMed ID: 15333287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
    Mocroft A; Sabin CA; Youle M; Madge S; Tyrer M; Devereux H; Deayton J; Dykhoff A; Lipman MC; Phillips AN; Johnson MA
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):401-7. PubMed ID: 10458621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
    Mocroft A; Ledergerber B; Katlama C; Kirk O; Reiss P; d'Arminio Monforte A; Knysz B; Dietrich M; Phillips AN; Lundgren JD;
    Lancet; 2003 Jul; 362(9377):22-9. PubMed ID: 12853195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
    Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
    AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.
    Raboud J; Anema A; Su D; Klein MB; Zakaryan A; Swan T; Palmer A; Hosein S; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg RS; Cooper C;
    HIV Clin Trials; 2012; 13(2):90-102. PubMed ID: 22510356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
    d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
    Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
    Mönkemüller KE; Call SA; Lazenby AJ; Wilcox CM
    Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
    Grabar S; Lanoy E; Allavena C; Mary-Krause M; Bentata M; Fischer P; Mahamat A; Rabaud C; Costagliola D;
    HIV Med; 2008 Apr; 9(4):246-56. PubMed ID: 18366449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.
    Jacobson MA; Zegans M; Pavan PR; O'Donnell JJ; Sattler F; Rao N; Owens S; Pollard R
    Lancet; 1997 May; 349(9063):1443-5. PubMed ID: 9164318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.
    Yust I; Fox Z; Burke M; Johnson A; Turner D; Mocroft A; Katlama C; Ledergerber B; Reiss P; Kirk O;
    Eur J Clin Microbiol Infect Dis; 2004 Jul; 23(7):550-9. PubMed ID: 15232720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.